ISSN 1725-2423

Official Journal of the European Union

C 22

English edition

Information and Notices

Volume 53

29 January 2010

Notice No | Contents | Page

EN

Price:
EUR 4

(Continued overleaf)

Court of Auditors

NOTICES FROM MEMBER STATES

V *Announcements*

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

EN

([1]) Text with EEA relevance

(Continued on inside back cover)

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Euro exchange rates [1]

28 January 2010

(2010/C 22/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,3999	AUD	Australian dollar	1,5537
JPY	Japanese yen	126,36	CAD	Canadian dollar	1,4824
DKK	Danish krone	7,4447	HKD	Hong Kong dollar	10,8755
GBP	Pound sterling	0,86160	NZD	New Zealand dollar	1,9695
SEK	Swedish krona	10,2021	SGD	Singapore dollar	1,9623
CHF	Swiss franc	1,4725	KRW	South Korean won	1 612,18
ISK	Iceland króna		ZAR	South African rand	10,6097
NOK	Norwegian krone	8,1790	CNY	Chinese yuan renminbi	9,5570
BGN	Bulgarian lev	1,9558	HRK	Croatian kuna	7,3210
CZK	Czech koruna	26,232	IDR	Indonesian rupiah	13 050,19
EEK	Estonian kroon	15,6466	MYR	Malaysian ringgit	4,7719
HUF	Hungarian forint	271,30	PHP	Philippine peso	65,232
LTL	Lithuanian litas	3,4528	RUB	Russian rouble	42,4650
LVL	Latvian lats	0,7083	THB	Thai baht	46,316
PLN	Polish zloty	4,0705	BRL	Brazilian real	2,5882
RON	Romanian leu	4,1360	MXN	Mexican peso	18,1179
TRY	Turkish lira	2,0898	INR	Indian rupee	64,7870

[1] *Source*: reference exchange rate published by the ECB.

Summary of Community decisions on marketing authorisations in respect of medicinal products from 1 November 2009 to 30 November 2009

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2010/C 22/02)

— Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004): Accepted

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
4.11.2009	Repaglinide Krka	Repaglinide	KRKA, d. d. Novo mesto Šmarješka cesta 6 SI-8501 Novo mesto SLOVENIJA	EU/1/09/579/001-018	Tablet	A10B X02	6.11.2009
4.11.2009	Copalia HCT	amlodipine besylate/valsartan/hydrochlorothiazide	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/09/575/001-060	Film-coated tablet	C09DX01	6.11.2009
4.11.2009	Dafiro HCT	amlodipine besylate/valsartan/hydrochlorothiazide	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/09/574/001-060	Film-coated tablet	C09DX01	6.11.2009
26.11.2009	Multaq	dronedarone	Sanofi-Aventis 174 avenue de France 75013 Paris FRANCE	EU/1/09/591/001-004	Film-coated tablet	Not applicable	1.12.2009
26.11.2009	Irbesartan/Hydrochlorothiazide Teva	hydrochlorothiazide	Teva Pharma B.V. Computerweg 10 3542 DR Utrecht NEDERLAND	EU/1/09/583/001-072	Film-coated tablet	C09D A04	1.12.2009

[1] OJ L 136, 30.4.2004, p. 1.

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
30.11.2009	Sildenafil Teva	Sildenafil	Teva Pharma B.V. Computerweg 10 3542 DR Utrecht NEDERLAND	EU/1/09/584/001-018	Film-coated tablet	G04BE03	2.12.2009
30.11.2009	Nevirapine Teva	nevirapine	Teva Pharma B.V. Computerweg 10 3542 DR Utrecht NEDERLAND	EU/1/09/598/001-004	Tablet	J05AG01	2.12.2009
30.11.2009	Hirobriz Breezhaler	Indacaterol	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/09/594/001-010	Inhalation powder	Not applicable	2.12.2009
30.11.2009	Onbrez Breezhaler	Indacaterol	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/09/593/001-010	Inhalation powder	Not applicable	2.12.2009
30.11.2009	Oslif Breezhaler	Indacaterol	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/09/586/001-010	Inhalation powder	Not applicable	2.12.2009
30.11.2009	Zutectra	Human Hepatitis B Immunoglobulin	Biotest Pharma GmbH Landsteinerstr. 5 63303 Dreieich DEUTSCHLAND	EU/1/09/600/001	Solution for injection	J06BB04	2.12.2009

— **Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
4.11.2009	Intelence	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/08/468/001	6.11.2009
4.11.2009	Optisulin	Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main DEUTSCHLAND	EU/1/00/133/001-032	6.11.2009
4.11.2009	Lantus	Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main DEUTSCHLAND	EU/1/00/134/001-037	6.11.2009
4.11.2009	Ketek	Aventis Pharma S.A. 20 avenue Raymond Aron 92160 Antony FRANCE	EU/1/01/191/001-005	6.11.2009
4.11.2009	Osseor	Les Laboratoires Servier 22 rue Garnier 92200 Neuilly-sur-Seine FRANCE	EU/1/04/287/001-006	6.11.2009
4.11.2009	Protelos	Les Laboratoires Servier 22 rue Garnier 92200 Neuilly-sur-Seine FRANCE	EU/1/04/288/001-006	6.11.2009
5.11.2009	Abilify	Otsuka Pharmaceutical Europe Ltd Hunton House Highbridge Business Park Oxford Road Uxbridge Middlesex UB8 1HU UNITED KINGDOM	EU/1/04/276/001-020 EU/1/04/276/024-036	10.11.2009
5.11.2009	Tyverb	Glaxo Group Limited Berkeley Avenue Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/07/440/001-002	9.11.2009
5.11.2009	Pre-pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/08/478/001	9.11.2009
5.11.2009	Celsentri	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/1/07/418/001-010	9.11.2009
5.11.2009	Invega	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/07/395/001-095	9.11.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
5.11.2009	Foscan	Biolitec Pharma Ltd United Drug House Magna Drive Dublin 24 IRELAND	EU/1/01/197/003-005	9.11.2009
6.11.2009	Fosavance	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU UNITED KINGDOM	EU/1/05/310/001-009	10.11.2009
9.11.2009	Januvia	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU UNITED KINGDOM	EU/1/07/383/001-018	11.11.2009
11.11.2009	Celvapan	Baxter AG Industriestraße 67 1221 Wien ÖSTERREICH	EU/1/08/506/001	12.11.2009
11.11.2009	Focetria	Novartis Vaccines and Diagnostics S.r.l. Via Fiorentina 1 53100 Siena SI ITALIA	EU/1/07/385/001-002 EU/1/07/385/004	12.11.2009
11.11.2009	Pandemrix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/08/452/001	12.11.2009
11.11.2009	Insuman	Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main DEUTSCHLAND	EU/1/97/030/028-195	13.11.2009
11.11.2009	PegIntron	Schering Plough Europe Rue de Stalle 73 1180 Bruxelles BELGIQUE Stallestraat 73 1180 Brussel BELGIË	EU/1/00/131/001-050	13.11.2009
11.11.2009	Soliris	Alexion Europe S.A.S. 25 boulevard de l'Amiral Bruix 75016 Paris FRANCE	EU/1/07/393/001	13.11.2009
11.11.2009	Rebetol	Schering Plough Europe Rue de Stalle 73 1180 Bruxelles BELGIQUE Stallestraat 73 1180 Brussel BELGIË	EU/1/99/107/001-005	13.11.2009
12.11.2009	Intelence	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/08/468/001	17.11.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
12.11.2009	IntronA	Schering Plough Europe Rue de Stalle 73 1180 Bruxelles BELGIQUE Stallestraat 73 1180 Brussel BELGIË	EU/1/99/127/001-044	17.11.2009
12.11.2009	ViraferonPeg	Schering Plough Europe Rue de Stalle 73 1180 Bruxelles BELGIQUE Stallestraat 73 1180 Brussel BELGIË	EU/1/00/132/001-050	17.11.2009
19.11.2009	IntronA	Schering Plough Europe Rue de Stalle 73 1180 Bruxelles BELGIQUE Stallestraat 73 1180 Brussel BELGIË	EU/1/99/127/031-039	23.11.2009
19.11.2009	Clopidogrel Teva Pharma	Teva Pharma B.V. Computerweg 10 3542 DR Utrecht NEDERLAND HCS bvba, H. Kennisstraat 53 2650 Edegem BELGIË	EU/1/09/561/001-009	23.11.2009
20.11.2009	Circadin	RAD Neurim Pharmaceuticals EEC Limited One Forbury Square The Forbury, Reading Berkshire RG1 3EB UNITED KINGDOM	EU/1/07/392/001-002	18.12.2009
20.11.2009	Bondronat	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW UNITED KINGDOM	EU/1/96/012/004 EU/1/96/012/009-013	24.11.2009
20.11.2009	Ebixa	H. Lundbeck A/S Ottiliavej 9 2500 Valby DANMARK	EU/1/02/219/001-003 EU/1/02/219/005-049	24.11.2009
20.11.2009	Mycamine	Astellas Pharma Europe B.V. Elisabethhof 19 2353 EW Leiderdorp NEDERLAND	EU/1/08/448/001-002	24.11.2009
20.11.2009	NeoRecormon	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW UNITED KINGDOM	EU/1/97/031/019-046	24.11.2009
20.11.2009	MabCampath	Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden NEDERLAND	EU/1/01/193/001-002	24.11.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
20.11.2009	Somavert	Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/1/02/240/001-004	24.11.2009
20.11.2009	Reyataz	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM	EU/1/03/267/001-010	24.11.2009
20.11.2009	Xeristar	Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein DEUTSCHLAND	EU/1/04/297/001-008	24.11.2009
20.11.2009	Regranex	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/99/101/001	24.11.2009
20.11.2009	Ziagen	Glaxo Group Ltd Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/99/112/001-002	24.11.2009
20.11.2009	Cymbalta	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/04/296/001-009	24.11.2009
20.11.2009	Angiox	The Medicines Company UK Ltd 115 L Milton Park Abingdon Oxfordshire OX14 4SA UNITED KINGDOM	EU/1/04/289/001-002	24.11.2009
20.11.2009	Agenerase	Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/00/148/001-004	24.11.2009
20.11.2009	RoActemra	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW UNITED KINGDOM	EU/1/08/492/001-006	24.11.2009
23.11.2009	Nexavar	Bayer Schering Pharma AG 13342 Berlin DEUTSCHLAND	EU/1/06/342/001	25.11.2009
23.11.2009	Noxafil	SP Europe Rue de Stalle 73 1180 Bruxelles BELGIQUE Stallestraat 73 1180 Brussel BELGIË	EU/1/05/320/001	25.11.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
23.11.2009	Pritor	Bayer Schering Pharma AG 13342 Berlin DEUTSCHLAND	EU/1/98/089/001-022	25.11.2009
23.11.2009	Aptivus	Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein DEUTSCHLAND	EU/1/05/315/001-002	26.11.2009
23.11.2009	Exjade	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/06/356/001-009	25.11.2009
23.11.2009	Cervarix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/07/419/001-012	25.11.2009
23.11.2009	Trizivir	Glaxo Group Ltd Greenford Road Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/00/156/002-003	25.11.2009
23.11.2009	Telzir	Glaxo Group Ltd Greenford Road Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/04/282/001-002	25.11.2009
23.11.2009	Azilect	Teva Pharma GmbH Kandelstrasse 10 79199 Kirchzarten DEUTSCHLAND	EU/1/04/304/001-007	25.11.2009
23.11.2009	Invega	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/07/395/001-095	25.11.2009
23.11.2009	Puregon	Organon N.V. Kloosterstraat 6 Postbus 20 5340 BH Oss NEDERLAND	EU/1/96/008/001-041	25.11.2009
23.11.2009	Kinzalmono	Bayer Schering Pharma AG 13342 Berlin DEUTSCHLAND	EU/1/98/091/001-014	25.11.2009
23.11.2009	Micardis	Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein DEUTSCHLAND	EU/1/98/090/001-020	26.11.2009
23.11.2009	Kaletra	Abbott Laboratories Ltd Queenborough Kent ME11 5EL UNITED KINGDOM	EU/1/01/172/001-007	25.11.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
24.11.2009	Synagis	Abbott Laboratories Ltd Queenborough Kent ME11 5EL UNITED KINGDOM	EU/1/99/117/001-002	26.11.2009
24.11.2009	alli	Glaxo Group Limited Berkeley Avenue Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/07/401/007-010	26.11.2009
25.11.2009	Kivexa	Glaxo Group Ltd Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/04/298/001-003	27.11.2009
26.11.2009	Enbrel	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH UNITED KINGDOM	EU/1/99/126/001-021	1.12.2009
26.11.2009	Enbrel	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH UNITED KINGDOM	EU/1/99/126/001-021	1.12.2009
26.11.2009	Diacomit	Biocodex 7 avenue Gallieni 94250 Gentilly FRANCE	EU/1/06/367/001-012	1.12.2009
26.11.2009	Intelence	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/08/468/001	1.12.2009
26.11.2009	Abseamed	Medice Arzneimittel Pütter GmbH & Co KG Kuhloweg 37 58638 Iserlohn DEUTSCHLAND	EU/1/07/412/021-026	1.12.2009
27.11.2009	Pandemrix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/08/452/001	30.11.2009
27.11.2009	Focetria	Novartis Vaccines and Diagnostics S.r.l. Via Fiorentina 1 53100 Siena SI ITALIA	EU/1/07/385/001-002 EU/1/07/385/004	30.11.2009
30.11.2009	Velcade	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/04/274/001-002	2.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
30.11.2009	Champix	Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/1/06/360/001-013	2.12.2009
30.11.2009	Adcirca	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/08/476/001-006	2.12.2009
30.11.2009	Docetaxel Winthrop	Aventis Pharma S.A. 20 avenue Raymond Aron 92165 Antony Cedex FRANCE	EU/1/07/384/003-004	2.12.2009
30.11.2009	Taxotere	Aventis Pharma S.A. 20 avenue Raymond Aron 92165 Antony Cedex FRANCE	EU/1/95/002/003-004	2.12.2009

— **Withdrawal of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
11.11.2009	Irbesartan BMS	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM	EU/1/06/375/001-033	13.11.2009
11.11.2009	Irbesartan HCT BMS	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM	EU/1/06/369/001-028	13.11.2009
12.11.2009	Clopidogrel BMS	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM	EU/1/08/464/001-019	17.11.2009
26.11.2009	Paxene	Norton Healthcare Limited Albert Basin Royal Docks London E16 2QJ UNITED KINGDOM	EU/1/99/113/001-004	10.12.2009

— **Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorisation	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
4.11.2009	Zolvix	Monepantel	Novartis Healthcare A/S Lyngbyvej 172 2100 Copenhagen DANMARK	EU/2/09/101/001-010	Oral solution	QP52AX09	6.11.2009

— **Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
18.11.2009	Dexdomitor	Orion Corporation Orionintie 1 FI-02200 Espoo SUOMI/FINLAND	EU/2/02/033/001-002	20.11.2009
19.11.2009	Improvac	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/2/09/095/001-003	23.11.2009
20.11.2009	Metacam	Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim am Rhein DEUTSCHLAND	EU/2/97/004/026 EU/2/97/004/033-034	24.11.2009
23.11.2009	Halocur	Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer NEDERLAND	EU/2/99/013/001-002	25.11.2009

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
UNITED KINGDOM

Summary of Community decisions on marketing authorisations in respect of medicinal products from 1 November 2009 to 30 November 2009

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council [1] *or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council* [2]*)*

(2010/C 22/03)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorisation	Member State concerned	Date of notification
6.11.2009	Arimidex	See Annex	See Annex	9.11.2009
26.11.2009	Multaq	Sanofi-Aventis 174 avenue de France 75013 Paris FRANCE	This Decision is addressed to the Member States	30.11.2009

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

ANNEX

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State (EU/EEA)	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical form	Route of administration
Austria	AstraZeneca Őesterreich GmbH Schwarzenbergplatz 7 1037 Wien ÖSTERREICH	Arimidex	1 mg	Film-coated tablets	Oral
Belgium	NV AstraZeneca SA Egide Van Ophemstraat 1180 Brussel BELGIË	Arimidex	1 mg	Film-coated tablets	Oral
Bulgaria	AstraZeneca Pharmaceuticals AB SE-151 85 Södertälje SVERIGE	Arimidex	1 mg	Film-coated tablets	Oral
Cyprus	AstraZeneca UK LTD Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Czech Republic	AstraZeneca UK Ltd Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Denmark	AstraZeneca A/S Roskildevej 22 2620 Albertslund DANMARK	Arimidex	1 mg	Film-coated tablets	Oral
Estonia	AstraZeneca UK Ltd 15 Stanhope Gate London W1K 1LN UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral

Member State (EU/EEA)	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical form	Route of administration
Finland	AstraZeneca Oy Luomanportti 3 FI-02200 Espoo SUOMI/FINLAND	Arimidex	1 mg	Film-coated tablets	Oral
France	AstraZeneca 1 place Renault 92844 Rueil-Malmaison Cedex FRANCE	Arimidex	1 mg	Film-coated tablets	Oral
Germany	AstraZeneca GmbH 22876 Wedel DEUTSCHLAND	Arimidex	1 mg	Film-coated tablets	Oral
Greece	AstraZeneca S.A. Theotokopoulou & Astronafton str 4 151 25 Maroussi Athens GREECE	Arimidex	1 mg	Film-coated tablets	Oral
Hungary	AstraZeneca Kft. Törökbálint Park u. 3. 2045 MAGYARORSZÁG/HUNGARY	Arimidex	1 mg	Film-coated tablets	Oral
Iceland	AstraZeneca UK Ltd Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Ireland	AstraZeneca UK Limited 600 Capability Green Luton LU1 3LU UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Italy	AstraZeneca S.p.A. Palazzo Volta Via F. Sforza 20080 Basiglio Milano MI ITALIA	Arimidex	1 mg	Film-coated tablets	Oral
Latvia	AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral

Member State (EU/EEA)	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical form	Route of administration
Lithuania	AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Luxembourg	NV AstraZeneca SA Rue Egide Van Ophem 1180 Bruxelles BELGIQUE	Arimidex	1 mg	Film-coated tablets	Oral
Malta	AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Netherlands	AstraZeneca BV Louis Pasteurlaan 5 2719 EE Zoetermeer NEDERLAND	Arimidex	1 mg	Film-coated tablets	Oral
Norway	AstraZeneca AS Hoffsveien 70B Box 200 Vinderen 0319 Oslo NORWAY	Arimidex	1 mg	Film-coated tablets	Oral
Poland	AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Portugal	AstraZeneca Produtos Farmacêuticos, Lda. Rua Humberto Madeira 7 Valejas 2745-663 Barcarena PORTUGAL	Arimidex	1 mg	Film-coated tablets	Oral
Romania	AstraZeneca UK Limited 600 Capability Green Luton LU1 3LU UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral

Member State (EU/EEA)	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical form	Route of administration
Slovakia	AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire SK10 2NA UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral
Slovenia	AstraZeneca UK Limited 15 Stanhope Gate London W1K 1LN UNITED KINGDOM	Arimidex 1 mg film-coated tablets	1 mg	Film-coated tablets	Oral
Spain	AstraZeneca Farmacéutica Spain, S.A. Parque Norte Edificio Roble C/ Serrano Galvache, 56 28033 Madrid ESPAÑA	Arimidex	1 mg	Film-coated tablets	Oral
Sweden	AstraZeneca AB SE-151 85 Södertälje SVERIGE	Arimidex	1 mg	Film-coated tablets	Oral
United Kingdom	AstraZeneca UK Limited 600 Capability Green Luton LU1 3LU UNITED KINGDOM	Arimidex	1 mg	Film-coated tablets	Oral

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2009 to 31 December 2009

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2010/C 22/04)

— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
3.12.2009	Olanzapine Glenmark Europe	Olanzapine	Glenmark Generics (Europe) Limited Laxmi House 2-B Draycott Avenue Kenton Harrow Middlesex HA3 OBU UNITED KINGDOM	EU/1/09/588/001-017	Orodispersible tablet	N05AH03	7.12.2009
3.12.2009	Olanzapine Glenmark	Olanzapine	Glenmark Generics (Europe) Limited Laxmi House 2-B Draycott Avenue Kenton Harrow Middlesex HA3 OBU UNITED KINGDOM	EU/1/09/587/001-012	Tablet	N05AH03	7.12.2009
9.12.2009	Prevenar 13	Pneumococcalpolysaccharide conjugate vaccine (13-valent, adsorbed)	Wyeth Lederle Vaccines S.A. Rue du Bosquet 15 1348 Louvain-la-Neuve BELGIQUE	EU/1/09/590/001-006	Suspension for injection	J07AL02	11.12.2009
10.12.2009	Lamivudine Teva Pharma B.V	Lamivudine	Teva Pharma B.V. Computerweg 10 3542 DR Utrecht NEDERLAND	EU/1/09/596/001-014	Film-coated tablet	J05AF05	14.12.2009
10.12.2009	Olazax Disperzi	Olanzapine	Glenmark Pharmaceuticals s.r.o City Tower Hvězdova 1716/2b 140 78 Praha 4 ČESKÁ REPUBLIKA	EU/1/09/592/001-005	Orodispersible tablet	N05AH03	14.12.2009

[1] OJ L 136, 30.4.2004, p. 1.

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
10.12.2009	Sildenafil Actavis	Sildenafil	Actavis Group PTC ehf. Reykjavikurvegi 76-78 220 Hafnarfjordur ICELAND	EU/1/09/595/001-015	Film-coated tablet	G04BE03	14.12.2009
11.12.2009	Olazax	Olanzapine	Glenmark Pharmaceuticals s.r.o. City Tower Hvězdova 1716/2b 140 78 Praha 4 ČESKÁ REPUBLIKA	EU/1/09/597/001-005	Tablet	N05AH03	15.12.2009
11.12.2009	Rivastigmine Hexal	Rivastigmine	HEXAL AG Industriestrasse 25 83607 Holzkirchen DEUTSCHLAND	EU/1/09/589/001-016 EU/1/09/589/017-018	Capsule, hard Oral solution	N06DA03	15.12.2009
11.12.2009	Rivastigmine Sandoz	Rivastigmine	Sandoz Pharmaceuticals GmbH Raiffeisenstraße 11 83607 Holzkirchen DEUTSCHLAND	EU/1/09/599/001-016 EU/1/09/599/017-018	Capsule, hard Oral solution	N06DA03	15.12.2009
23.12.2009	Zenas	Amifampridine	EUSA Pharma SAS 3 allée des Séquoias 69760 Limonest FRANCE	EU/1/09/601/001	Tablet	N07XX05	28.12.2009
23.12.2009	Sildenafil ratiopharm	Sildenafil	Ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm DEUTSCHLAND	EU/1/09/603/001-012	Film-coated tablet	G04BE03	28.12.2009

— **Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
3.12.2009	Champix	Pfizer Ltd. Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/1/06/360/001-013	7.12.2009
3.12.2009	Rasilez	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/07/405/001-040	7.12.2009
8.12.2009	Xigiris	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/02/225/001-002	10.12.2009
8.12.2009	Renagel	Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden NEDERLAND	EU/1/99/123/005-013	10.12.2009
9.12.2009	Stocrin	Merck Sharp & Dohme Ltd. Hertford Road Hoddesdon Hertfordshire EN11 9BU UNITED KINGDOM	EU/1/99/111/001-005 EU/1/99/111/008-011	11.12.2009
9.12.2009	Sustiva	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM	EU/1/99/110/001-005 EU/1/99/110/008-010	11.12.2009
9.12.2009	Pandemrix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/08/452/001	11.12.2009
10.12.2009	Effentora	Cephalon Europe 5 rue Charles Martigny 94700 Maisons-Alfort FRANCE	EU/1/08/441/001-010	14.12.2009
10.12.2009	Effentora	Cephalon Europe 5 rue Charles Martigny 94700 Maisons-Alfort FRANCE	EU/1/08/441/001-010	14.12.2009
10.12.2009	Synflorix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/09/508/001-010	14.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
10.12.2009	Truvada	Gilead Sciences International Limited Cambridge CB21 6GT UNITED KINGDOM	EU/1/04/305/001-002	14.12.2009
10.12.2009	Fendrix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/04/299/001-003	14.12.2009
10.12.2009	EVOLTRA	Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden NEDERLAND	EU/1/06/334/001-005	14.12.2009
10.12.2009	Revatio	Pfizer Limited Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/1/05/318/002	24.12.2009
11.12.2009	Kivexa	Glaxo Group Ltd. Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/04/298/001-003	16.12.2009
11.12.2009	Clopidogrel Mylan Pharma	Apotex Europe B.V. Darwingweg 20 2333 CR Leiden NEDERLAND Mylan S.A.S. 117 allée des Parcs 69800 Saint Priest FRANCE	EU/1/09/568/001-018	16.12.2009
11.12.2009	Rivastigmine 1A Pharma	1A Pharma GmbH Keltenring 1+3 82041 Oberhaching DEUTSCHLAND	EU/1/09/585/001-018	16.12.2009
11.12.2009	EVICEL	OMRIX biopharmaceuticals S.A./N.V. Chaussée de Waterloo/Waterloosesteenweg 200 1640 Rhode-St-Genèse/Sint-Genesius-Rode BELGIQUE/BELGIË	EU/1/08/473/001-003	15.12.2009
11.12.2009	Abseamed	Medice Arzneimittel Pütter GmbH & Co KG Kuhloweg 37 58638 Iserlohn DEUTSCHLAND	EU/1/07/412/001-020	15.12.2009
14.12.2009	Efient	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/08/503/001-016	16.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
14.12.2009	Exalief	BIAL-Portela & Ca, SA A Av. da Siderurgia Nacional 4745-457 S. Mamede do Coronado PORTUGAL	EU/1/09/520/001-020	17.12.2009
14.12.2009	Zebinix	BIAL-Portela & Ca, SA A Av. da Siderurgia Nacional 4745-457 S. Mamede do Coronado PORTUGAL	EU/1/09/514/001-020	17.12.2009
16.12.2009	REVLIMID	Celgene Europe Limited Riverside House Riverside Walk Windsor Berkshire SL4 1NA UNITED KINGDOM	EU/1/07/391/001-004	18.12.2009
18.12.2009	Docetaxel Winthrop	Aventis Pharma S.A. 20 avenue Raymond Aron 92165 Antony Cedex FRANCE	EU/1/07/384/001-004	22.12.2009
18.12.2009	Emtriva	Gilead Sciences International Limited Cambridge CB21 6GT UNITED KINGDOM	EU/1/03/261/003	22.12.2009
18.12.2009	Adenuric	Ipsen Pharma 65 quai Georges Gorse 92100 Boulogne-Billancourt FRANCE Menarini International Operations Luxembourg S.A. 1, avenue de la Gare 1611 Luxembourg LUXEMBOURG	EU/1/08/447/001-004	22.12.2009
18.12.2009	Aloxi	Helsinn Birex Pharmaceuticals Ltd. Damastown Mulhuddart Dublin 15 IRELAND	EU/1/04/306/001	22.12.2009
16.12.2009	Binocrit	Sandoz GmbH Biochemiestraße 10 6250 Kundl ÖSTERREICH	EU/1/07/410/001-026	18.12.2009
16.12.2009	Epoetin alfa hexal	Hexal AG. Industriestraße 25 83607 Holzkirchen DEUTSCHLAND	EU/1/07/411/001-026	21.12.2009
16.12.2009	Silapo	STADA Arzneimittel AG Stadastraße 2—18 61118 Bad Vilbel DEUTSCHLAND	EU/1/07/432/001-022	18.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
18.12.2009	Litak	Lipomed GmbH Hegenheimer Straße 2 79576 Weil/Rhein DEUTSCHLAND	EU/1/04/275/001-002	22.12.2009
21.12.2009	AZARGA	Alcon Laboratories (UK) Ltd. Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UD UNITED KINGDOM	EU/1/08/482/001-002	23.12.2009
21.12.2009	Altargo	Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/07/390/001-004	24.12.2009
21.12.2009	Zyprexa Velotab	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/99/125/001-016	23.12.2009
21.12.2009	Avastin	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW UNITED KINGDOM	EU/1/04/300/001-002	23.12.2009
21.12.2009	LYRICA	Pfizer Ltd. Ramsgate Road Sandwich Kent CT13 9NJ UNITED KINGDOM	EU/1/04/279/001-043	24.12.2009
21.12.2009	Taxotere	Aventis Pharma S.A. 20 avenue Raymond Aron 92165 Antony Cedex FRANCE	EU/1/95/002/001-004	23.12.2009
21.12.2009	Zyprexa	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/96/022/002 EU/1/96/022/004 EU/1/96/022/006 EU/1/96/022/009-012 EU/1/96/022/014 EU/1/96/022/016-017 EU/1/96/022/019-034	23.12.2009
21.12.2009	Revasc	Canyon Pharmaceuticals Ltd. 20-22 Bedford Row London WC1R 4JS UNITED KINGDOM	EU/1/97/043/001-003	11.1.2010
21.12.2009	RAPAMUNE	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH UNITED KINGDOM	EU/1/01/171/001 EU/1/01/171/007-010	23.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
21.12.2009	SOLIRIS	Alexion Europe S.A.S. 25 Boulevard de l'Amiral Bruix 75016 Paris FRANCE	EU/1/07/393/001	23.12.2009
21.12.2009	Vimpat	UCB Pharma SA. Allée de la Recherche 66/ Researchdreef 60 1070 Bruxelles/Brussel BELGIQUE/BELGIË	EU/1/08/470/001-017	28.12.2009
21.12.2009	ZONEGRAN	Eisai Limited European Knowledge Centre Mosquito Way Hatfield Hertfordshire AL10 9SN UNITED KINGDOM	EU/1/04/307/001-013	24.12.2009
21.12.2009	ZYPADHERA	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten NEDERLAND	EU/1/08/479/001-003	23.12.2009
21.12.2009	Agenerase	Glaxo Group Limited Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/00/148/001-004	23.12.2009
21.12.2009	Irbesartan HCT Winthrop	Sanofi Pharma Bristol Myers Squibb SNC 174 avenue de France 75013 Paris FRANCE	EU/1/06/377/001-028	23.12.2009
21.12.2009	KARVEZIDE	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM	EU/1/98/085/001-034	23.12.2009
21.12.2009	Tevagrastim	Teva Generics GmbH Wasastraße 50 01445 Radebeul DEUTSCHLAND	EU/1/08/445/001-014	23.12.2009
21.12.2009	Avamys	Glaxo Group Ltd. Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/07/434/001-003	24.12.2009
21.12.2009	Thelin	Encysive (UK) Limited Alder Castle House 10 Noble Street London EC2V 7QJ UNITED KINGDOM	EU/1/06/353/001-005	24.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
21.12.2009	Volibris	Glaxo Group Ltd. Greenford Middlesex UB6 0NN UNITED KINGDOM	EU/1/08/451/001-004	24.12.2009
22.12.2009	CELVAPAN	Baxter AG Industriestraße 67 1221 Wien ÖSTERREICH	EU/1/08/506/001	23.12.2009
22.12.2009	Pandemrix	GlaxoSmithKline Biologicals S.A. Rue de l'Institut 89 1330 Rixensart BELGIQUE	EU/1/08/452/001	23.12.2009
22.12.2009	Stelara	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/08/494/001-002	24.12.2009
22.12.2009	Tasigna	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM	EU/1/07/422/001-004	24.12.2009
22.12.2009	Replagal	Shire Human Genetic Therapies AB Svärdvägen 11D SE-182 33 Danderyd SVERIGE	EU/1/01/189/001-006	28.12.2009
22.12.2009	Evra	Janssen-Cilag International NV Turnhoutseweg 30 2340 Beerse BELGIË	EU/1/02/223/001-003	24.12.2009
22.12.2009	Crixivan	Merck Sharp & Dohme Ltd. Hertford Road Hoddesdon Hertfordshire EN11 9BU UNITED KINGDOM	EU/1/96/024/001-005 EU/1/96/024/008 EU/1/96/024/010	24.12.2009
22.12.2009	Onsior	Novartis Animal Health UK Ltd. Frimley Business Park Frimley/Camberley Surrey GU16 7SR UNITED KINGDOM	EU/2/08/089/001-021	24.12.2009
22.12.2009	RELISTOR	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH UNITED KINGDOM	EU/1/08/463/001-003	24.12.2009

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
23.12.2009	Tractocile	Ferring Pharmaceuticals A/S Kay Fiskers Plads 11 2300 Copenhagen S DANMARK	EU/1/99/124/001-002	28.12.2009
23.12.2009	Biograstim	CT Arzneimittel GmbH Lengeder Straße 42a 13407 Berlin DEUTSCHLAND	EU/1/08/450/001-010	29.12.2009
23.12.2009	Retacrit	HOSPIRA Enterprises B.V. Taurusavenue 19-21b 2132 LS Hoofddorp NEDERLAND	EU/1/07/431/001-025	31.12.2009
23.12.2009	TORISEL	Wyeth Europa Ltd Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH UNITED KINGDOM	EU/1/07/424/001	4.1.2010
23.12.2009	IVEMEND	Merck Sharp & Dohme Limited Hertford Road Hoddesdon Hertfordshire EN11 9BU UNITED KINGDOM	EU/1/07/437/001-002	4.1.2010
23.12.2009	Alisade	Glaxo Group Ltd, Greenford Middlesex UB6 ONN UNITED KINGDOM	EU/1/08/474/001-003	4.1.2010
23.12.2009	Focetria	Novartis Vaccines and Diagnostics S.r.l. Via Fiorentina 1 Siena SI ITALIA	EU/1/07/385/001-002 EU/1/07/385/004	28.12.2009

— **Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
14.12.2009	Aivlosin	ECO Animal Health Ltd. 78 Coombe Road New Malden Surrey KT3 4QS UNITED KINGDOM	EU/2/04/044/011-012-013	16.12.2009
18.12.2009	Equioxx	MERIAL 29 avenue Tony Garnier 69007 Lyon FRANCE	EU/2/08/083/002-003	22.12.2009
21.12.2009	Flexicam	Dechra Veterinary Products A/S Mekuvej 9 7171 Uldum DANMARK Omnipharm Ltd. The Spire Egypt Road Nottingham NG7 7GD UNITED KINGDOM	EU/2/06/058/001-004	23.12.2009

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
UNITED KINGDOM

Summary of Community decisions on marketing authorisations in respect of medicinal products from 1 December 2009 to 31 December 2009

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC of the European Parliament and of the Council [1] *or Article 38 of Directive 2001/82/EC of the European Parliament and of the Council* [2]*)*

(2010/C 22/05)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorisation	Member State concerned	Date of notification
16.12.2009	REVLIMID	Celgene Europe Limited Riverside House Riverside Walk Windsor Berkshire SL4 1NA UNITED KINGDOM	This Decision is addressed to the Member States	17.12.2009
10.12.2009	Effentora	Cephalon Europe 5 rue Charles Martigny 94700 Maisons-Alfort FRANCE	This Decision is addressed to the Member States	11.12.2009
21.12.2009	Revatio	Pfizer Limited Sandwich Kent CT13 9NJ UNITED KINGDOM	This Decision is addressed to the Member States	22.12.2009

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

COURT OF AUDITORS

Special Report No 17/2009 'concerning vocational training actions for women co-financed by the European Social Fund'

(2010/C 22/06)

The European Court of Auditors hereby informs you that Special Report No 17/2009 'concerning vocational training actions for women co-financed by the European Social Fund' has just been published.

The report can be accessed for consultation or downloading on the European Court of Auditors' website: http://www.eca.europa.eu

A hard copy and a CD-ROM version of the report may be obtained free of charge on request to the Court of Auditors:

European Court of Auditors
Communication and Reports Unit
12, rue Alcide De Gasperi
1615 Luxembourg
LUXEMBOURG

Tel. +352 4398-1
E-mail: euraud@eca.europa.eu

or by filling in an electronic order form on EU-Bookshop.

NOTICES FROM MEMBER STATES

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 800/2008 declaring certain categories of aid compatible with the common market in application of Articles 87 and 88 of the Treaty (General Block Exemption Regulation)

(Text with EEA relevance)

(2010/C 22/07)

Reference number of State Aid	X 636/09
Member State	Spain
Member State reference number	—
Name of the Region (NUTS)	Castilla-La Mancha Article 87(3)(a)
Granting authority	Consejería de Educación y Ciencia de la Junta de Comunidades de Castilla-La Mancha Río Alberche, s/n 45071 Toledo ESPAÑA http://www.educa.jccm.es
Title of the aid measure	Subvenciones complementarias de ayudas cdti en i+d de interés para Castilla-La Mancha
National legal basis (Reference to the relevant national official publication)	Ley 38/2003, de 17 de noviembre, general de subvenciones (B.O.E. Nº 276 de 18.11.2003)
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	7.3.2009-31.12.2012
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 3,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Industrial research (Article 31(2)(b))	10 %	—
Experimental development (Article 31(2)(c))	10 %	—

Web link to the full text of the aid measure:

http://docm.jccm.es/portaldocm/descargarArchivo.do?ruta=2009/03/06/pdf/2009_3138.pdf&tipo=rutaDocm

---

Reference number of State Aid	X 638/09
Member State	Czech Republic
Member State reference number	25580/09/08100
Name of the Region (NUTS)	Střední Cechy, Jihozápad, Severozápad, Severovýchod, Jihovýchod, Střední Morava, Moravskoslezko Article 87(3)(a)
Granting authority	Ministerstvo průmyslu a obchodu Na Františku 32 110 15 Praha 1 ČESKÁ REPUBLIKA http://www.mpo.cz
Title of the aid measure	Nemovitosti–2. výzva
National legal basis (Reference to the relevant national official publication)	Zákon č. 47/2002 Sb, o podpoře malého a středního podnikání; Zákon č. 218/2000 Sb., o rozpočtových pravidlech a o změně některých souvisejících zákonů; Zákon č. 513/1991 Sb., obchodní zákoník.
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	1.7.2009-30.4.2012
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	CZK 4 000,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	Strukturální fondy-ERDF – 85 % – 600,00 CZK (v milionech)

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Regional investment and employment aid (Article 13) Scheme	40 %	20 %

Web link to the full text of the aid measure:

http://www.mpo.cz/dokument38212.html

Reference number of State Aid	X 639/09
Member State	Belgium
Member State reference number	BE
Name of the Region (NUTS)	région Wallonne Mixed
Granting authority	Service public de Wallonie DGO6 «Économie, emploi et recherche» Place de la Wallonie, 1 bât 2 5100 Jambes BELGIQUE http://economie.wallonie.be
Title of the aid measure	Incitants en faveur des entreprises destinés à favoriser la protection de l'environnement et l'utilisation durable de l'énergie
National legal basis (Reference to the relevant national official publication)	Décret du 11 mars 2004 relatif aux incitants destinés à favoriser la protection de l'environnement et l'utilisation durable de l'énergie (M.B. du 8.4.2004, p. 19628) Arrêté du gouvernement wallon du 2 décembre 2004 portant exécution du décret du 11 mars 2004 relatif aux incitants destinés à favoriser la protection de l'environnement et l'utilisation durable de l'énergie modifié par l'arrêté du Gouvernement du 14 mai 2009 (M.B. du 17.6.2009, p. 42421)
Type of measure	Scheme
Amendment of an existing aid measure	Modification N 15/03
Duration	27.6.2009-31.12.2013
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 15,00 million
For guarantees	—
Aid Instrument (Article 5)	Fiscal measure, Grant
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Investment aid enabling undertakings to go beyond Community standards for environmental protection or increase the level of environmental protection in the absence of Community standards (Article 18)	30 %	10 %
Aid for early adaptation to future Community standards for SMEs (Article 20)	15 %	—
Environmental investment aid for energy saving measures (Article 21)	20 %	20 %
Environmental investment aid for high efficiency cogeneration (Article 22)	30 %	20 %
Environmental investment aid for the promotion of energy from renewable energy sources (Article 23)	30 %	20 %

Web link to the full text of the aid measure:

http://wallex.wallonie.be/index.php?doc=3770&rev=3099-8724

http://wallex.wallonie.be/index.php?doc=3774&rev=3103-3436

Reference number of State Aid	X 640/09
Member State	Ireland
Member State reference number	—
Name of the Region (NUTS)	—
Granting authority	Sustainable Energy Ireland Wilton Park House Wilton Place Dublin 2 IRELAND http://www.sei.ie
Title of the aid measure	Supports for Exemplar Energy Efficiency Projects (SEEEP)
National legal basis (Reference to the relevant national official publication)	Support for Exemplar Energy Efficiency Projects programme manual
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	1.7.2009-31.12.2009
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 1,50 million

For guarantees	—	
Aid Instrument (Article 5)	Grant	
Reference to the Commission Decision	—	
If co-financed by Community funds	—	
Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Investment aid enabling undertakings to go beyond Community standards for environmental protection or increase the level of environmental protection in the absence of Community standards (Article 18)	35 %	—

Web link to the full text of the aid measure:

http://www.sei.ie/your_business/public_sector/grants

Reference number of State Aid	X 642/09
Member State	Netherlands
Member State reference number	VENW/DGMO-2009/6185
Name of the Region (NUTS)	Nederland Mixed
Granting authority	Minister van Verkeer en Waterstaat Postbus 20901 2500 EX Den Haag NEDERLAND http://www.verkeerenwaterstaat.nl/
Title of the aid measure	Regeling van de Minister van Verkeer en Waterstaat houdende bepalingen met betrekking tot de verstrekking van subsidies voor duurzame mobiliteit, logistiek en duurzaam waterbeheer (Kaderregeling subsidies duurzaamheid verkeer en waterstaat)
National legal basis (Reference to the relevant national official publication)	Regeling van de Minister van Verkeer en Waterstaat houdende bepalingen met betrekking tot de verstrekking van subsidies voor duurzame mobiliteit, logistiek en duurzaam waterbeheer (Kaderregeling subsidies duurzaamheid verkeer en waterstaat) De Kaderregeling subsidie duurzaamheid verkeer en waterstaat is gebaseerd op de Kaderwet subsidies Verkeer en Waterstaat
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	15.7.2009-15.7.2015
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 125,00 million

For guarantees	—
Aid Instrument (Article 5)	Other, Grant, Repayable advances — Aangezien specificatie/toelichting in Deel II niet mogelijk is, is deze informatie hier opgenomen (geen ander instrument): Steun voor fundamenteel onderzoek: ook in de vorm van terugbetaalbaar voorschot mogelijk Steun voor industrieel onderzoek: naast verhoging voor kmo, ook verhoging van 15 % tot maximaal 80 % mogelijk (art. 31, lid 4 sub b GBER) Steun voor experimentele ontwikkeling: naast verhoging voor kmo, ook verhoging van 15 % mogelijk (art. 31, lid 4 sub b GBER) Steun voor technische haalbaarheidsstudies: 65 % (indust.) 40 % (exp.), met kmo-verhoging van 10 % Overige kmo-verhogingen: max. 20 % (KO) en 10 % (MO) Steun voor het uitlenen van hooggekwalificeerd personeel: 50 % gedurende max. drie jaar per onderneming of entiteit en per ingeleende werknemer
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Aid for environmental studies (Article 24)	50 %	20 %
Aid for consultancy in favour of SMEs (Article 26)	50 %	—
Aid for SME participation in fairs (Article 27)	50 %	—
Fundamental research (Article 31(2)(a))	100 %	—
Industrial research (Article 31(2)(b))	50 %	20 %
Experimental development (Article 31(2)(c))	25 %	20 %
Aid for technical feasibility studies (Article 32)	75 %	—
Aid for innovation advisory services and for innovation support services (Article 36)	EUR 200 000,00	—
Aid for the loan of highly qualified personnel (Article 37)	—	—
General training (Article 38(2))	60 %	20 %

Web link to the full text of the aid measure:

http://zoek.officielebekendmakingen.nl/stcrt-2009-10400.html

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 800/2008 declaring certain categories of aid compatible with the common market in application of Articles 87 and 88 of the Treaty (General Block Exemption Regulation)

(Text with EEA relevance)

(2010/C 22/08)

Reference number of State Aid	X 661/09	
Member State	Germany	
Member State reference number	—	
Name of the Region (NUTS)	Deutschland Article 87(3)(a)	
Granting authority	Bundesamt für Wirtschaft und Ausfuhrkontrolle Postfach 5160 65726 Eschborn DEUTSCHLAND http://www.bafa.de	
Title of the aid measure	Richtlinie zur Förderung von Maßnahmen an gewerblichen Kälteanlagen vom 1.9.2008, zuletzt geändert am 1.1.2009	
National legal basis (Reference to the relevant national official publication)	Bundesanzeiger, Juni 2008, S. 2344 http://www.bundesanzeiger.de/old/banz/banzinha/BAnz_60_096.htm	
Type of measure	Scheme	
Amendment of an existing aid measure	—	
Duration	1.9.2008-31.12.2012	
Economic sector(s) concerned	All economic sectors eligible to receive aid	
Type of beneficiary	SME large enterprise	
Annual overall amount of the budget planned under the scheme	EUR 40,00 million	
For guarantees	—	
Aid Instrument (Article 5)	Grant	
Reference to the Commission Decision	—	
If co-financed by Community funds	—	
Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Environmental investment aid for energy saving measures (Article 21)	58 %	—

Web link to the full text of the aid measure:

http://www.bmu.de/files/pdfs/allgemein/application/pdf/foerderrichtlinie_kaelte.pdf

http://www.kaelte-effizienz.de

Reference number of State Aid	X 662/09
Member State	Germany
Member State reference number	—
Name of the Region (NUTS)	Deutschland Article 87(3)(a)
Granting authority	Bundesamt für Wirtschaft und Ausfuhrkontrolle Postfach 5160 65726 Eschborn DEUTSCHLAND http://www.bafa.de
Title of the aid measure	Richtlinie zur Förderung von Mini-KWK-Anlagen vom 1.9.2008, zuletzt geändert am 1.1.2009
National legal basis (Reference to the relevant national official publication)	Bundesanzeiger, Juni 2008, S. 2342 http://www.bundesanzeiger.de/old/banz/banzinha/BAnz_60_096.htm
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	1.9.2008-31.12.2012
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 20,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Environmental investment aid for high efficiency cogeneration (Article 22)	28 %	—

Web link to the full text of the aid measure:

http://www.mini-kwk.de

http://www.bmu.de/files/pdfs/allgemein/application/pdf/foerderrichtlinie_minikwk.pdf

Reference number of State Aid	X 663/09
Member State	Estonia
Member State reference number	—

Name of the Region (NUTS)	Estonia Article 87(3)(a)
Granting authority	Ettevõtluse Arendamise Sihtasutus Lasnamäe 2 11412 Tallinn EESTI/ESTONIA http://www.eas.ee
Title of the aid measure	Kompetentsikeskuste arendamine
National legal basis (Reference to the relevant national official publication)	Regionaalministri 3. juuli 2009. aasta määrus nr 10 „Meetme „Kompetentsikeskuste arendamine“ tingimused“ (RTL, 13.7.2009, 56, 820).
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	16.7.2009-31.12.2013
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EEK 60,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	Euroopa Regionaalarengu Fond – 60,00 EEK (miljonites)

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Regional investment and employment aid (Article 13) Scheme	50 %	20 %
Industrial research (Article 31(2)(b))	50 %	—
Experimental development (Article 31(2)(c))	25 %	—

Web link to the full text of the aid measure:

http://www.riigiteataja.ee/ert/act.jsp?id=13201666

———

Reference number of State Aid	X 665/09
Member State	Italy
Member State reference number	itd1
Name of the Region (NUTS)	Bolzano-Bozen Article 87(3)(c)

Granting authority	Provincia autonoma di Bolzano Ripartizione 39 Affari comunitari — Ufficio FSE Via Conciapelli 69 39100 Bolzano BZ ITALIA http://www.provincia.bz.it/fse
Title of the aid measure	Regime quadro d'aiuti della Provincia autonoma di Bolzano, ai sensi degli articoli 38 e 39 del regolamento (CE) n. 800/2008 del 6 agosto 2008: aiuti destinati alle imprese operanti nel territorio della Provincia autonoma di Bolzano appartenenti ai settori esposti alla concorrenza internazionale e che sono rivolti alla formazione, alla riqualificazione ed aggiornamento dei loro addetti.
National legal basis (Reference to the relevant national official publication)	Delibera della Giunta provinciale n. 1653 del 22.6.2009 pubblicata nel Bollettino Ufficiale della Regione autonoma Trentino — Alto Adige n. 29 del 14.7.2009. Legge provinciale 29 luglio 1986, n. 20 — Progetti di formazione professionale da realizzare con i contributi del fondo sociale europeo
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	22.6.2009-30.6.2014
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 10,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	Programma operativo regionale FSE 2007-2013 della Provincia autonoma di Bolzano (2007 IT 052 PO 009) — 22,70 milioni di EUR

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Specific training (Article 38(1))	25 %	20 %
General training (Article 38(2))	60 %	20 %

Web link to the full text of the aid measure:

http://www.provincia.bz.it/europa/fse/temi/559.asp

http://www.provincia.bz.it/europa/fse/download/Regime_quadro_aiuti_formazione_it_de.pdf

http://www.provinz.bz.it/europa/esf/themen/559.asp

Reference number of State Aid	X 666/09
Member State	Latvia

Member State reference number	—
Name of the Region (NUTS)	Latvia Article 87(3)(a)
Granting authority	LR Vides ministrija Peldu iela 25 Rīga, LV-1494 LATVIJA http://www.vidm.gov.lv
Title of the aid measure	atklātais konkurss "Vides tehnoloģijas un ekoinovācija"
National legal basis (Reference to the relevant national official publication)	Ministru kabineta 2009. gada 13. janvāra noteikumi Nr. 43 "Eiropas Ekonomikas zonas finanšu instrumenta līdzfinansētās programmas "Vides politikas integrācijas programma Latvijā" apakšprojektu iesniegumu atklāta konkursa "Vides tehnoloģijas un ekoinovācija" nolikums" (publicēts: Latvijas Vēstnesis, 3.2.2009., Nr. 18)
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	6.2.2009-31.12.2010
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	LVL 1,80 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Regional investment and employment aid (Article 13) Scheme	50 %	20 %
Experimental development (Article 31(2)(c))	25 %	20 %

Web link to the full text of the aid measure:

http://www.likumi.lv/doc.php?id=187239

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 800/2008 declaring certain categories of aid compatible with the common market in application of Articles 87 and 88 of the Treaty (General Block Exemption Regulation)

(Text with EEA relevance)

(2010/C 22/09)

Reference number of State Aid	X 660/09	
Member State	Germany	
Member State reference number	—	
Name of the Region (NUTS)	Hamburg Non-assisted areas	
Granting authority	Behörde für Stadtentwicklung und Umwelt Stadthausbrücke 8 20355 Hamburg DEUTSCHLAND http://www.hamburg.de/umwelt	
Title of the aid measure	Vorerwärmung von Kesselspeisewasser durch Wärmerückgewinnung	
National legal basis (Reference to the relevant national official publication)	§ 44 LHO (Hamburg)	
Type of measure	Ad hoc aid HOBUM Oleochemicals GmbH	
Amendment of an existing aid measure	—	
Date of granting	1.7.2009	
Economic sector(s) concerned	Manufacture of chemicals and chemical products	
Type of beneficiary	SME	
Overall amount of the ad hoc aid awarded to the undertaking	EUR 0,01 million	
For guarantees	—	
Aid Instrument (Article 5)	Grant	
Reference to the Commission Decision	—	
If co-financed by Community funds	—	
Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Environmental investment aid for energy saving measures (Article 21)	30 %	—

Web link to the full text of the aid measure:

http://www.hamburg.de/start-teilnehmer/1281752/eg-gruppenfreistellungsverordnung.html

Reference number of State Aid	X 669/09
Member State	Poland
Member State reference number	PL
Name of the Region (NUTS)	Poland Article 87(3)(a)
Granting authority	Narodowe Centrum Badań i Rozwoju ul. ks. Skorupki 4 00-546 Warszawa POLSKA/POLAND http://www.ncbir.gov.pl
Title of the aid measure	Udzielanie pomocy za pośrednictwem Narodowego Centrum Badań i Rozwoju
National legal basis (Reference to the relevant national official publication)	Artykuł 4 ust. 5 ustawy z dnia 15 czerwca 2007 r. o Narodowym Centrum Badań i Rozwoju (Dz. U. Nr 115, poz. 789), rozporządzenie Ministra Nauki i Szkolnictwa Wyższego z dnia 20 maja 2009 r. w sprawie warunków i trybu udzielania pomocy publicznej za pośrednictwem Narodowego Centrum Badań i Rozwoju (Dz. U. Nr 89, poz. 732)
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	18.6.2009-31.12.2013
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	PLN 80,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Fundamental research (Article 31(2)(a))	100 %	—
Industrial research (Article 31(2)(b))	80 %	20 %
Experimental development (Article 31(2)(c))	60 %	20 %
Aid for technical feasibility studies (Article 32)	75 %	—
Aid for industrial property rights costs for SMEs (Article 33)	100 %	—
Aid for innovation advisory services and for innovation support services (Article 36)	PLN 880 900	—
Aid for the loan of highly qualified personnel (Article 37)	PLN 200 000	—

Web link to the full text of the aid measure:

http://www.ncbir.pl/www/images/doc/spb/Konkurs/Rozporzadzenie%20o%20pomocy%20pulicznej.pdf

Reference number of State Aid	X 670/09
Member State	Austria
Member State reference number	—
Name of the Region (NUTS)	Oberoesterreich Mixed
Granting authority	Amt der oberösterreichischen Landesregierung Amt der oö LR Dirketion Verfassungsdienst 4021 Linz ÖSTERREICH http://www.ooe.gv.at
Title of the aid measure	Förderungsrichtlinien des Landes Oberösterreich für gewässerökologische Maßnahmen für Wettbewerbsteilnehmer
National legal basis (Reference to the relevant national official publication)	Allgemeine Förderungsrichtlinien des Landes Oberösterreich
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	6.7.2009-31.10.2013
Economic sector(s) concerned	All economic sectors eligible to receive aid
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	EUR 2,00 million
For guarantees	—
Aid Instrument (Article 5)	Grant
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
Investment aid enabling undertakings to go beyond Community standards for environmental protection or increase the level of environmental protection in the absence of Community standards (Article 18)	10 %	24 %

Web link to the full text of the aid measure:

http://www.land-oberoesterreich.gv.at/cps/rde/xchg/SID-595A8C2F-ACA92550/ooe/hs.xsl/86736_DEU_HTML.htm

---

Reference number of State Aid	X 671/09
Member State	United Kingdom
Member State reference number	—

Name of the Region (NUTS)	East Midlands, West Midlands Article 87(3)(c)
Granting authority	Birmingham City University City North Campus Birmingham West Midlands B42 2SU UNITED KINGDOM http://www.bcu.ac.uk
Title of the aid measure	The HEFCE Economic Challenge Investment Fund (ECIF)
National legal basis (Reference to the relevant national official publication)	A higher education corporation by virtue of the Education Reform Act 1988
Type of measure	Scheme
Amendment of an existing aid measure	—
Duration	27.4.2009-30.9.2010
Economic sector(s) concerned	Manufacturing, water supply; sewerage, waste management and remediation activities, construction, wholesale and retail trade; repair of motor vehicles and motorcycles, real estate activities
Type of beneficiary	SME large enterprise
Annual overall amount of the budget planned under the scheme	GBP 0,33 million
For guarantees	—
Aid Instrument (Article 5)	Other — Training Programme
Reference to the Commission Decision	—
If co-financed by Community funds	—

Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
General training (Article 38(2))	80 %	—

Web link to the full text of the aid measure:

http://www.bcu.ac.uk/docs/downloads/business/ECIF%20GBER%20Info%20for%20the%20BCU%20website%20-%203.08.09.doc

http://www.bcu.ac.uk/gber

Reference number of State Aid	X 673/09
Member State	United Kingdom
Member State reference number	—
Name of the Region (NUTS)	Northern Ireland Article 87(3)(c)

Granting authority	InterTradeIreland Old Gasworks Business Park Kilmorey Street Newry Co. Down Northern Ireland BT34 2DE UNITED KINGDOM http://www.intertradeireland.com	
Title of the aid measure	Fusion — Phase III	
National legal basis (Reference to the relevant national official publication)	European Communities Act 1972 British Irish Agreement Act 1999 Section 2.3 Part 7 of Annex II of the Act empowers InterTradeIreland to invest, grant aid or lend for the purposes of its function	
Type of measure	Scheme	
Amendment of an existing aid measure	Modification XT 46a/04	
Duration	8.6.2009-31.12.2013	
Economic sector(s) concerned	All economic sectors eligible to receive aid	
Type of beneficiary	SME large enterprise	
Annual overall amount of the budget planned under the scheme	GBP 2,50 million	
For guarantees	—	
Aid Instrument (Article 5)	Grant	
Reference to the Commission Decision	—	
If co-financed by Community funds	—	
Objectives	Maximum aid intensity in % or maximum aid amount in national currency	SME-bonuses in %
General training (Article 38(2))	60 %	20 %

Web link to the full text of the aid measure:

http://www.statutelaw.gov.uk/legResults.aspx?ActiveTextDocId=1374459&sourœ=OPSI

http://www.intertradeireland.com/index.cfm/area/information/page/State%20Aid

V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

EUROPEAN COMMISSION

Communication from the Minister for Economic Affairs of the Kingdom of the Netherlands pursuant to Article 3(2) of Directive 94/22/EC of the European Parliament and of the Council on the conditions for granting and using authorisations for the prospection, exploration and production of hydrocarbons

(2010/C 22/10)

The Minister for Economic Affairs hereby gives notice that an application has been received for authorisation to prospect for hydrocarbons in block segment L11c as indicated on the map appended as Annex 3 to the Mining Regulation (*Mijnbouwregeling*) (Government Gazette (*Staatscourant*) 2002, No 245).

With reference to the Directive mentioned in the introduction and Article 15 of the Mining Act (*Mijnbouwwet*) (Bulletin of Acts and Decrees (*Staatsblad*) 2002, No 542), the Minister for Economic Affairs hereby invites interested parties to submit a competing application for authorisation to prospect for hydrocarbons in block segment L11c of the Dutch continental shelf.

The Minister for Economic Affairs is the competent authority for the granting of authorisations. The criteria, conditions and requirements referred to in Articles 5(1), 5(2) and 6(2) of the above-mentioned Directive are set out in the Mining Act (Bulletin of Acts and Decrees 2002, No 542).

Block segment L11c is delimited by the parallel arcs between vertex pairs A-B and C-D, the meridian arc between vertices B and C and the great circle between vertex pairs D-E and E-A.

The coordinates of the vertices are as follows:

A 4° 33′ 3,100″ E and 53° 30′ 0,000″

B 4° 40′ 0,000″ E and 53° 30′ 0,000″

C 4° 40′ 0,000″ E and 53° 20′ 0,000″

D 4° 34′ 0,000″ E and 53° 20′ 0,000″

E 4° 29′ 2,000″ E and 53° 24′ 57,000″

Applications may be submitted during the 13 weeks following the publication of this notice in the *Official Journal of the European Union* and should be sent to:

De Minister van Economische Zaken
ter attentie van drs. J.C. De Groot, directeur Energiemarkt
ALP A/562
Postbus 20101
2500 EC Den Haag
NEDERLAND

Applications received after the expiry of this period will not be considered.

A decision on the applications will be taken not later than 12 months after this period has expired.

Further information can be obtained by calling Mr P.C. de Regt on the following telephone number: +31 703797382.

OTHER ACTS

EUROPEAN COMMISSION

Publication of an amendment application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

(2010/C 22/11)

This publication confers the right to object to the amendment application pursuant to Article 7 of Council Regulation (EC) No 510/2006. Statements of objection must reach the Commission within six months of the date of this publication.

AMENDMENT APPLICATION

COUNCIL REGULATION (EC) No 510/2006

Amendment application pursuant to Article 9

'CAPPERO DI PANTELLERIA'

EC No: IT-PGI-0317-0307-29.05.2007

PGI (X) PDO ( )

1. **Heading in the specification affected by the amendment:**

— ☐ Name of product

— ☒ Description of product

— ☐ Geographical area

— ☐ Proof of origin

— ☒ Method of production

— ☐ Link

— ☐ Labelling

— ☒ National requirements

— ☐ Other (to be specified)

2. **Type of amendment(s):**

— ☐ Amendment to Single Document or Summary Sheet

— ☒ Amendment to Specification of registered PDO or PGI for which neither the Single Document nor the Summary has been published

— ☐ Amendment to Specification that requires no amendment to the published Single Document (Article 9(3) of Regulation (EC) No 510/2006)

— ☐ Temporary amendment to Specification resulting from imposition of obligatory sanitary or phytosanitary measures by public authorities (Article 9(4) of Regulation (EC) No 510/2006)

3. **Amendment(s):**

3.1. *Description:*

The possibility of using a maximum of 10 % of other varieties has been removed so as further to strengthen the link between the product and its area of origin.

The values for the product's principal characteristics have been replaced by ranges that more accurately reflect local production conditions.

3.2. *Method of production:*

The planting density has been amended since the distance concerned was difficult for the inspection body to check and so was therefore superfluous.

The maximum density per hectare has been increased from 1 500 plants to 2 000 and consequently the maximum yield per hectare has been increased from 2 250 to 3 000 kg.

The harvesting period and the quantity of salt used in preparation have been specified so as to make the production specification more exact and inspection more effective.

3.3. *National requirements:*

The provisions that conferred upon the Sicilian regional authorities tasks that more properly fall within the remit of the approved inspection body have been deleted.

The arrangements for the checks carried out by the competent inspection body have been brought into line with Articles 10 and 11 of Regulation (EC) No 510/2006.

SINGLE DOCUMENT

COUNCIL REGULATION (EC) No 510/2006

'CAPPERO DI PANTELLERIA'

EC No: IT-PGI-0317-0307-29.05.2007

PGI (X) PDO ( )

1. **Name:**

'Cappero di Pantelleria'

2. **Member State or Third Country:**

Italy

3. **Description of the agricultural product or foodstuff:**

3.1. *Type of product (Annex III):*

Class 1.6. Fruit, vegetables and cereals, fresh or processed

3.2. *Description of the product to which the name in (1) applies:*

On release for consumption, 'Cappero di Pantelleria' is spherical or almost spherical, rarely oblong or conical, and green to mustard-coloured. It has a strong, aromatic smell, with no trace of mould or extraneous odours. It has the aromatic, salty flavour characteristic of Pantelleria capers with sea salt. Capers used in the production of 'Cappero di Pantelleria' must be from plants of the botanical species 'Capperis spinosa', variety 'inermis', cultivar 'nocellara'. Other characteristics are:

— moisture content: from 50 % to 70 %,

— size: from 4 mm to 15 mm,

— sea salt in the pack: no more than 25 % of the weight of the capers.

3.3. *Raw materials (for processed products only):*

—

3.4. *Feed (for products of animal origin only):*

—

3.5. *Specific steps in production that must take place in the identified geographical area:*

All stages in the growing and preparation of 'Cappero di Pantelleria', from sowing to harvesting and subsequent salting, must take place exclusively on the Island of Pantelleria using local production methods. Harvesting must be by hand and must be staggered, leaving buds that are not sufficiently ripe on the plant. The capers must be dry salted using exclusively sea salt.

3.6. *Specific rules concerning slicing, grating, packaging, etc.:*

—

3.7. *Specific rules concerning labelling:*

In the designation and presentation of the Protected Geographical Indication 'Cappero di Pantelleria', the words 'Cappero di Pantelleria' and 'Indicazione geografica protetta' (Protected Geographical Indication) must be printed in characters of the same size and colour.

The label must also bear the name, company name and address of the packer, the address of the undertaking preparing the product on Pantelleria, the production batch and the net weight as sold. Additional information may be given in another field of vision, provided this is not of a laudatory nature and does not mislead the consumer as to the nature and characteristics of the product.

4. **Concise definition of the geographical area:**

The production area of 'Cappero di Pantelleria' is the entire Island of Pantelleria in the Province of Trapani.

5. **Link with the geographical area:**

5.1. *Specificity of the geographical area:*

The Island of Pantelleria is of volcanic origin and is extremely arid, due to very little rainfall, and therefore is an ideal environment for growing capers.

5.2. *Specificity of the product:*

Over the centuries, this product has become widely known for its aroma and taste. Thus the need to protect this product from other similar products grown in the Mediterranean basin but lacking its particular qualities.

The extent of the area involved, the special care taken in cultivation and the creation of efficient processing and marketing structures have made the caper plant a special crop on the island, constituting an important source of income.

5.3. *Causal link between the geographical area and the quality or characteristics of the product (for PDO) or a specific quality, the reputation or other characteristic of the product (for PGI):*

The first specific, historically verified evidence for Pantelleria capers comes from the essay by Professor P. Calcara, 'Breve cenno sulla geognosia ed agricultura dell'isola di Pantelleria' ('A Short Account of the Geognosy and Agriculture of the Island of Pantelleria'), published in Palermo in 1855 in the 'Giornale della Commissione d'Agricoltura e Pastorizia in Sicilia' (Journal of the Commission on Arable and Livestock Farming in Sicily).

This essay points out the economic-commercial value of the caper for the society of Pantelleria at that time: 'The caper grows spontaneously along the southern coast and on the arid cliffs of the island, and the poor gather the buds in the months of July and August, before they flower, and sell them to a class of people who, after separating them according to size, press them in brine or vinegar and then put them on the market'.

The economic value of the caper for Pantelleria is also confirmed by other reliable historical sources such as the 1894 edition of the German Brockhaus encyclopaedia, under the entry 'Pantelleria', and Dr Pietro Brignone Boccanera in his 'Cenni Storici su Pantelleria' ('A Historical Account of Pantelleria'), published in Partanna in 1908, which states that, beginning in the second half of the 19th century, '… the caper was cultivated and the island achieved production of 60 000 kg of capers'.

This is sufficient to show the increasing importance of the caper in the island's economy, even if secondary to the growing of grapes, and especially 'zibibbo' grapes. More recently, from the beginning of the 1960s, caper growing surpassed grape growing in importance and both the area under capers and caper production itself have continued to increase, the latter reaching around 1 200 tonnes in 1983.

Reference to publication of the specification:

The Ministry launched the national objection procedure with the publication of the amendment proposal for the Protected Geographical Indication 'Cappero di Pantelleria' in the *Gazzetta Ufficiale della Repubblica Italiana*.

The full text of the product specification is available at the following site:

http://www.politicheagricole.it/DocumentiPubblicazioni/Search_Documenti_Elenco.htm?txtTipo Documento=Disciplinare%20in%20esame%20UE&txtDocArgomento=Prodotti%20di%20Qualit%E0> Prodotti%20Dop,%20Igp%20e%20Stg

or

by going directly to the home page of the Ministry (http://www.politicheagricole.it) and clicking on 'Prodotti di Qualità' (on the left of the screen) and finally on 'Disciplinari di Produzione all'esame dell'UE [regolamento (CE) n. 510/2006]'.

Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

(2010/C 22/12)

This publication confers the right to object to the application pursuant to Article 7 of Regulation (EC) No 510/2006. Statements of objection must reach the Commission within six months of the date of this publication.

SUMMARY

COUNCIL REGULATION (EC) No 510/2006

'ASPARAGO DI BADOERE'

EC No: IT-PGI-0005-0495-21.09.2005

PDO ( ) PGI (X)

This summary sets out the main elements of the product specification for information purposes.

1. **Responsible department in the Member State:**

Name: Ministero delle Politiche Agricole e Forestali
Address: Via XX Settembre 20
00187 Roma RM
ITALIA

Tel. +39 0646655202
Fax +39 0646655306
E-mail: saco7@politicheagricole.it

2. **Group:**

Name: Consorzio dell'Asparago di Badoere
Address: c/o Municipio di Morgano
Piazza Indipendenza 2
31050 Badoere di Morgano TV
ITALIA

Tel. +39 0499350001
Fax +39 0499350001
E-mail: —
Composition: Producers/processors (X) other ( )

3. **Type of product:**

Class 1.6. Fresh or processed fruit, vegetables and cereals

4. **Specification:**

(summary of requirements under Article 4(2) of Regulation (EC) No 510/2006)

4.1. *Name:*

'Asparago di Badoere'

4.2. *Description:*

'Asparago di Badoere' must consist of shoots grown from plants of the Liliacee family (genus *Asparagus* — species *Officinalis* — from the 'Dariana', 'Thielim', 'Zeno', 'Avalim' and 'Grolim' varieties for white asparagus and 'Eros', 'Thielim', 'Grolim', 'Dariana' and 'Avalim' for green).

When released for consumption, both types of 'Asparago di Badoere' PGI must be: intact, sound, free from damage caused by unsuitable washing, clean, fresh in appearance and colour, free from pests or damage caused by pests, unbruised, free of abnormal external moisture or any foreign smell and/or taste, crunchy, not hollow and not peeled. The cut at the base must be clean and perpendicular to the stem. In particular, white Extra Class 'Asparago di Badoere' PGI has a straight shoot with a very compact tip; it is white, but may develop a faint pink tint after packaging; it has a sweet taste, is neither acidic nor salty, is tender and not at all fibrous, has a slight scent of fresh vegetables and ripe corn, and barely perceptible bitter marbling; it has a diameter of between 12 and 20 mm, with a maximum variation of 6 mm between the thickest and the thinnest shoot in the same bundle or package, and a length of between 14 and 22 cm, with a maximum variation of 1 cm between the shortest and the longest shoot in the same bundle or package. White Class I 'Asparago di Badoere' PGI has the same characteristics as the Extra Class product as regards conformation, colour, taste and length, but is between 10 and 22 mm in diameter, with a maximum variation of 8 mm between the thickest and the thinnest shoot in the same bundle or package. Green Extra Class 'Asparago di Badoere' PGI has a straight shoot, possibly slightly curved at the top, and a very compact tip; the tip is a dark, glossy green and may have a violet tint, while the base (no more than 5 % of the shoot) is green with violet to white shading; it has a distinctive sweet taste, is neither acidic nor salty nor bitter, is tender and not at all fibrous, and has a lingering fruity, herbaceous scent; it has a diameter of between 12 and 20 mm, with a maximum variation of 6 mm between the thickest and the thinnest shoot in the same bundle, and a length of between 18 and 27 cm, with a maximum variation of 1 cm between the shortest and the longest shoot in the same bundle. Green Class I 'Asparago di Badoere' PGI has the same characteristics as the Extra Class product as regards conformation, colour and taste, but is between 10 and 22 mm in diameter, with a maximum variation of 8 mm between the thickest and the thinnest shoot in the same bundle, between 16 and 27 cm in length, with a maximum variation of 1 cm between the shortest and the longest shoot in the same bundle.

For all classes and types, a maximum tolerance of 3 % is allowed.

4.3. *Geographical area:*

The production area of 'Asparago di Badoere' PGI consists of the municipalities of Piombino Dese and Trebaseleghe in the Province of Padua, Casale sul Sile, Casier, Istrana, Mogliano Veneto, Morgano, Paese, Preganziol, Quinto di Treviso, Resana, Treviso, Vedelago and Zero Branco in the Province of Treviso and Scorzè in the Province of Venice. 'Asparago di Badoere' PGI may be produced only on land within this geographical area that satisfies the conditions set out under point 4.6 below.

4.4. *Proof of origin:*

Each stage in the production process is monitored, with all inputs and outputs recorded. This — along with the compilation of specific registers managed by the inspection body listing producers, packagers and the land registry parcels in which production takes place, and notification to the inspection body of the quantities produced — ensures product traceability throughout the production chain. All legal and natural persons recorded in the registers are subject to checks by the inspection body in line with the production specifications and the relevant monitoring plan.

4.5. *Method of production:*

'Asparago di Badoere' (both types) may be grown in glasshouses or outdoors. The 'crowns' must be planted between 1 February and 30 June, with a maximum planting density of 22 000 plants/hectare. In any case, the crop cannot be grown again or following other types of Liliacea for at least 36 months. In addition, land may not be used for growing the asparagus for at least twelve months following crops of potatoes, carrots, beet or legumes.

Organic or chemical fertilisers may be used once a year, provided this involves at least one treatment with organic fertilisers. Chemical fertilisation may not, however, exceed the following unit values:

— nitrogen (N) — 150 kg/ha,

— phosphorous (P_2O_5) — 100 kg/ha,

— potassium (K_2O) — 200 kg/ha.

The crop must be maintained in optimum condition by carrying out regular mechanical or chemical pest and weed control.

In order to ensure healthy growth, no shoots may be harvested for at least 18 months from the date of planting, i.e. in the main growth period.

White asparagus plants must be mulched and covered with a black plastic sheet at least 0,10 mm thick, or another suitable material, in order to slow normal photosynthesis.

Harvesting must take place between 1 February and 31 May each year, i.e. after the main growth period.

The maximum yield after cleaning may not exceed 7 000 kg/hectare.

In order to ensure traceability and control and maintain consistent product quality, 'Asparago di Badoere' must be grown and packaged within the area defined in point 4.3.

4.6. *Link:*

Both types of 'Asparago di Badoere' are characterised by rapid growth, ensuring that shoots have the physical properties of low fibre content and particularly bright colouring, and the distinctive organoleptic properties described in point 4.2.

Together, the soil and climate conditions in the production area (see below) are essential to ensuring the quality and originality of 'Asparago di Badoere' as they are responsible for its characteristic physical and organoleptic properties.

Temperatures in the production area average around 15 °C, with possible highs of 30 °C in the course of the year. The average annual rainfall of around 900 mm is normally concentrated in the spring and autumn. The conditions mean that there is no need for irrigation during the harvesting period, so the plants are not subject to any form of water stress and thus deliver top quality Badoere asparagus. In addition, the land is fertile and productive thanks to the slow-running karst rivers (the Sile, Zero and Dese and their tributaries) flowing through the production area. This makes the plants extremely robust, removing the need for any fertilisation beyond that outlined in point 4.5. In addition, low nitrogen levels allow the shoots to grow intact without visible splits or cracks. The earth in the production area is loose. 'Asparago di Badoere' can be grown only in deep soil with a fairly coarse to medium texture, low calcium content at the surface, subalkaline to neutral pH and good to medium drainage, with possible calcium carbonate ('caranto') deposits deeper down.

There is a long tradition of asparagus growing in the Veneto Region, which appears to originate from the time the Romans conquered land there.

There are countless documentary sources mentioning 'Asparago di Badoere', both white and green, as one of the most sought-after local products of the Veneto. In addition, it is worth remembering that the importance of Badoere in producing asparagus in the province led the municipal administration of Morgano to organise the first provincial Asparagus Fair in 1968, a tradition which still continues today. Asparagus growing is deeply ingrained in the local culture of the production area, where growing techniques are handed down from one generation to the next. The particular blend of production factors, such as the manual nature and small scale of the activity, combines with the local soil and climate conditions to make this type of activity clearly distinct from the rest of the sector. The widespread distribution and reputation of 'Asparago di Badoere', achieved thanks to a series of promotional campaigns, testify to the high esteem in which it is held.

4.7. *Inspection body:*

The inspection body complies with standard EN 45011.

Name: CSQA Certificazioni srl
Address: Via S. Gaetano 74
36016 Thiene VI
ITALIA

Tel. +39 0445366094
Fax +39 0445382672
E-mail: —

4.8. *Labelling:*

Asparagus labelled 'Asparago di Badoere' PGI must be packaged in bundles tightly tied with raffia or in suitable food packaging. The content of each package must be uniform and comprise only asparagus of the same type, quality class and thickness.

Bundles and packaging must bear a label featuring in lettering of the same size the wording 'Asparago di Badoere PGI', with specific reference to the type (green or white), the name or company name and the address of the producer and packager, plus the marketing class (Extra or I), the thickness and any further details required by the rules in force.

The seal of guarantee must also be affixed to each bundle or package in such a way that the seal (containing the 'Asparago di Badoere' PGI logo and any other indication required by the rules in force) is broken when the bundle or package is opened.

The 'Asparago di Badoere' PGI logo comprises a square with rounded edges, at the centre of which is a graphical image divided into two levels. In the foreground is a stylised representation of five asparagus shoots in a bundle. The background shows an architectural detail of a *barchessa* (open barn) in the town square, with a curved, outlined edging dividing the two levels. On the lower right-hand section is the wording 'Asparago di Badoere' on two lines.

OTHER ACTS

European Commission

EN

2010 SUBSCRIPTION PRICES (excluding VAT, including normal transport charges)

EU Official Journal, L + C series, paper edition only	22 official EU languages	EUR 1 100 per year
EU Official Journal, L + C series, paper + annual CD-ROM	22 official EU languages	EUR 1 200 per year
EU Official Journal, L series, paper edition only	22 official EU languages	EUR 770 per year
EU Official Journal, L + C series, monthly CD-ROM (cumulative)	22 official EU languages	EUR 400 per year
Supplement to the Official Journal (S series), tendering procedures for public contracts, CD-ROM, two editions per week	multilingual: 23 official EU languages	EUR 300 per year
EU Official Journal, C series — recruitment competitions	Language(s) according to competition(s)	EUR 50 per year

Subscriptions to the *Official Journal of the European Union*, which is published in the official languages of the European Union, are available for 22 language versions. The Official Journal comprises two series, L (Legislation) and C (Information and Notices).

A separate subscription must be taken out for each language version.

In accordance with Council Regulation (EC) No 920/2005, published in Official Journal L 156 of 18 June 2005, the institutions of the European Union are temporarily not bound by the obligation to draft all acts in Irish and publish them in that language. Irish editions of the Official Journal are therefore sold separately.

Subscriptions to the Supplement to the Official Journal (S Series — tendering procedures for public contracts) cover all 23 official language versions on a single multilingual CD-ROM.

On request, subscribers to the *Official Journal of the European Union* can receive the various Annexes to the Official Journal. Subscribers are informed of the publication of Annexes by notices inserted in the *Official Journal of the European Union*.

CD-Rom formats will be replaced by DVD formats during 2010.

Sales and subscriptions

Subscriptions to various priced periodicals, such as the subscription to the *Official Journal of the European Union*, are available from our commercial distributors. The list of commercial distributors is available at:

http://publications.europa.eu/others/agents/index_en.htm

EUR-Lex (http://eur-lex.europa.eu) offers direct access to European Union legislation free of charge. The *Official Journal of the European Union* can be consulted on this website, as can the Treaties, legislation, case-law and preparatory acts.

For further information on the European Union, see: http://europa.eu

Publications Office of the European Union
2985 Luxembourg
LUXEMBOURG

EN